An electrode assembly for sensing an electrochemical signal diffused from a source to a working electrode which is comprised of a plurality of substantially separated working electrode surfaces is disclosed. The electrode of the invention is comprised of 1) a working electrode made up of a plurality of working electrode surfaces or components and 2) a electrically insulating gap defined by adjacent edges of 1) insulating the working electrode surfaces or components from each other. The working electrode components are configured to receive electrochemical signal from two or preferably three dimensions simultaneously. The working electrode components configured over the same surface as a single electrode provide (1) an improved signal to noise ratio as compared to a single electrode by reducing noise, and (2) provide an overall enhanced signal after sensing for a given period of time.

Patent
   RE38681
Priority
Mar 25 1997
Filed
Dec 02 2002
Issued
Jan 04 2005
Expiry
Mar 25 2017

TERM.DISCL.
Assg.orig
Entity
Large
159
47
all paid
12. A method of measuring an amount or concentration of glucose in a mammalian subject, the method comprising the steps of:
extracting the glucose from the subject by providing current to an electroosmotic electrode sufficient to create diffusion of glucose across a mammalian subject's skin, through a hydrogel medium and to a working electrode, said hydrogel medium comprising water, electrolyte, and glucose oxidase, wherein the thickness of said hydrogel is in the range of 10 μm to 1,000 μm, and said working electrode comprised of a plurality of substantially physically separated electrode surfaces and an electroosmotic electrode, wherein (i) the working electrode surfaces are separated by a gap having a width in a range of 10 μm to 1,000 μm, (ii) an electrically insulating material is positioned in each gap separating the electrode surfaces, (iii) the working electrode is characterized by a substantially planar configuration, and (iv) the working electrode has a thickness in a range of 0.25 μm to 250 μm;
converting glucose into gluconic acid and hydrogen peroxide by catalysis using glucose oxidase,
producing an electrical current at the working electrode surfaces, wherein said electrical current is generated at the working electrode surfaces by electrochemical oxidation of hydrogen peroxide;
measuring the electrical current generated by the electrochemical oxidation at the working electrode surfaces; and
correlating the measured current to the amount or concentration of glucose in the mammalian subject.
1. A method of measuring an amount or concentration of a chemical signal in a mammalian subject, the method comprising the steps of:
extracting the chemical signal from the subject by providing current to an electroosmotic electrode sufficient to create diffusion of a chemical signal across a mammalian subject's skin, through a hydrogel medium and to a working electrode, said hydrogel medium comprising water, electrolyte, and an enzyme, wherein the thickness of said hydrogel is in the range of 10 μm to 1,000 μm, and said working electrode comprised of a plurality of substantially physically separated electrode surfaces and an electroosmotic electrode, wherein (i) the working electrode surfaces are separated by a gap having a width in a range of 10 μm to 1,000 μm, (ii) an electrically insulating material is positioned in each gap separating the electrode surfaces, (iii) the working electrode is characterized by a substantially planar configuration, and (iv) the working electrode has a thickness in a range of 0.25 μm to 250 μm;
providing a voltage to each of the working electrode surfaces of the working electrode sufficient to drive electrochemical detection of chemical signal which generates an electrical current at the working electrode surfaces, wherein said electrical current is generated at the working electrode surfaces by electrochemical oxidation of hydrogen peroxide producing an electrical signal;
measuring the electrical current generated at the working electrode surfaces; and
correlating the measured current to the amount or concentration of chemical signal in the mammalian subject.
2. The method of claim 1, wherein the working electrode surfaces are configured as elongated rectangular strips parallel to each other and separated from each other by elongated rectangular gaps.
3. The method of claim 1, wherein the electrode surfaces are configured in a regular pattern of planar surfaces and gaps.
4. The method of claim 1, wherein the working electrode surfaces are provided as a plurality of square-shaped regions, with the working electrode surfaces being isolated from each other by a plurality of rectangular gaps.
5. The method of claim 4, wherein the rectangular gaps are squares.
6. The method of claim 1, wherein each working electrode surface is comprised of a compound selected from the group consisting of platinum, platinum oxides, platinum dioxides, and platinum alloys.
7. The method of claim 1, further comprising a counter electrode and a reference electrode and wherein the counter electrode and reference electrode are positioned in substantially the same plane as the working electrode, the counter electrode being electrically connected to the working electrode, and the reference electrode being positioned such that a substantially constant electrical potential is maintained on the reference electrode relative to the working electrode.
8. The method of claim 7, wherein the working electrode, counter electrode, reference electrode, and electroosmotic electrode are concentrically aligned with each other and wherein the working electrode is operated at a current level in the range of 0.1 nanoamp to 1 milliamp.
9. A The method of claim 8, wherein the hydrogel medium has a surface in contact with a surface of the working electrode, the counter electrode, the reference electrode, and the electroosmotic electrode.
10. The method of claim 1, wherein the chemical signal is glucose.
11. The method of claim 10, wherein the enzyme is glucose oxidase.
13. The method of claim 12, wherein the working electrode surfaces are configured as elongated rectangular strips parallel to each other and separated from each other by elongated rectangular gaps.
14. The method of claim 12, wherein the electrode surfaces are configured in a regular pattern of planar surfaces and gaps.
15. The method of claim 12, wherein the working electrode surfaces are provided as a plurality of square-shaped regions, with the working electrode surfaces being isolated from each other by a plurality of rectangular gaps.
16. The method of claim 15, wherein the rectangular gaps are squares.
17. The method of claim 12, wherein each working electrode surface is comprised of a compound selected from the group consisting of platinum, platinum oxides, platinum dioxides, and platinum alloys.
18. The method of claim 12, further comprising a counter electrode and a reference electrode and wherein the counter electrode and reference electrode are positioned in substantially the same plane as the working electrode, the counter electrode being electrically connected to the working electrode, and the reference electrode being positioned such that a substantially constant electrical potential is maintained on the reference electrode relative to the working electrode.
19. The method of claim 18, wherein the working electrode, counter electrode, reference electrode, and electroosmotic electrode are concentrically aligned with each other and wherein the working electrode is operated at a current level in the range of 0.1 nanoamp to 1 milliamp.
20. The method of claim 19, wherein the hydrogel medium has a surface in contact with a surface of the working electrode, the counter electrode, the reference electrode, and the electroosmotic electrode.

This application is a continuation of U.S. patent application Ser. No. 08/824,143, filed Mar. 25, 1997, which is now U.S. Pat. No. 6,139,718, from which application priority is claimed pursuant to 35 U.S.C. §120 and which application are incorporated herein by reference in its entirety.

The invention relates generally to the field of electrodes for electrochemical measurements, specifically electrodes used in the biomedical fields to measure concentrations of biomedically significant compounds.

The amount of a chemical in a given volume of solution can be measured with an electrode. An electrode is the component in an electrochemical cell in contact with the electrolyte medium through which current can flow by electronic movement. Electrodes, which are essential components of both galvanic (current producing) and electrolytic (current using) cells, can be composed of a number of electrically conductive materials, e.g., lead, zinc, aluminum, copper, iron, nickel, mercury, graphite, gold, or platinum. Examples of electrodes are found in electric cells, where they are dipped in the electrolyte; in medical devices, where the electrode is used to detect electrical impulses emitted by the heart or the brain; and in semiconductor devices, where they perform one or more of the functions of emitting, collecting, or controlling the movements of electrons and ions.

The electrolyte can be any substance that provides ionic conductivity, and through which electrochemically active species can diffuse. Electrolytes can be solid, liquid, or semisolid (e.g., in the form of a gel). Common electrolytes include sulfuric acid and sodium chloride, which ionize in solution. Electrolytes used in the medical field must have a pH that is sufficiently close to that of the tissue in contact with the electrode (e.g., skin) so as not to cause harm to the tissue over time.

Electrochemically active species that are present in the electrolyte can undergo electrochemical reactions (oxidation or reduction) at the surface of the electrode.

The rate at which the electrochemical reactions take place is related to the reactivity of the species, the electrode material, the electrical potential applied to the electrode, and the rate at which the electrochemically active species is transported to the electrode surface.

In unstirred electrolytes, such as quiescent liquid solutions and gel electrolytes, diffusion is the main process of transport of electrochemically active species to the electrode surface. The exact nature of the diffusion process is determined by the geometry of the electrode (e.g., planar disk, cylindrical, or spherical), and the geometry of the electrolyte (e.g., semiinfinite large volume, thin disk of gel, etc.) For example, diffusion of electrochemically active species to a spherical electrode in a semiinfinite volume of electrolyte differs from diffusion of electrochemically active species to a planar disk electrode. At the center of the disk electrode the diffusion of the electroactive species towards the electrode is in a substantially perpendicular direction, whereas at the edges of the disk electrode the diffusion comes from both perpendicular and radial directions. The combination of these two different diffusion patterns makes the total current collected at the disk electrode.

The present invention makes use of a unique geometry of the electrode surface such that the diffusion of the electrochemically active species in the radial and axial direction gives a total signal higher than if there was only diffusion in the axial direction, thus allowing the use of a decreased surface area of the electrode surface, particularly for the case of an electrolyte of finite volume.

An electrode assembly is disclosed that includes a multicomponent working electrode subassembly comprised of a plurality of substantially physically separated working electrode surfaces (e.g., a plurality of working electrode components). When surfaces of the working electrode subassembly are configured over an area that is equal to the area of a single piece working electrode, the multicomponent electrode will provide an improved signal to noise ratio due to reduced noise, and will provide an enhanced signal when measuring signal from a finite amount of medium over a finite amount of time. A working electrode of the invention provides a substantially discontinuous surface area in contact with a medium through which a compound will diffuse in response to a current. Noise created by the electrode material is reduced by reducing the surface area per individual working electrode surface, and the signal is enhanced by allowing diffusion to multiple working electrode surfaces via two and preferably three dimensions, e.g., (1) normal to the main surface plane, (2) normal to the length edge, and (3) normal to the width edge. By using a substantially discontinuous surface, a large number of edges are provided within the area being monitored. In the presence of edges, the flux for the species of interest is significantly higher (at the edge, due to radial diffusion) thus giving a higher overall flux over the area of interest that is greater than that if there was only diffusion directly perpendicular to the main surface plane of the electrode of interest.

The invention features an electrode subassembly comprised of interconnected electrode surfaces that form a working electrode, with each of the electrode components being separated from the others by an electrically insulating gap.

An object of the invention is to provide a working electrode comprised of substantially discontinuous working electrode surfaces or components and thereby obtain signal from three dimensions which provide an improved signal to noise ratio.

Another object is to provide a method for measuring an electrochemical signal by providing substantially discontinuous working electrode surfaces or components that detect the flux of the electrochemical signal in two or more preferably three directions relative to the working electrode surface.

Another object of the invention is to provide an electrode subassembly composed of a working electrode comprised of substantially discontinuous working electrode surfaces for use with an electrode assembly to measure accurately, consistently, and quickly a diffused electrochemical signal, and achieve an accurate measurement of the electrochemical signal within a matter of seconds to minutes.

Another object of the invention is to provide an electrode assembly with a bonding pad or a pad that contacts a pin connector that can be readily connected and disconnected from a power source and monitoring device, thus allowing for replacement of the electrode assembly, electrode subassembly, and/or an ionically conductive material (e.g., an electrolytic gel) used with the electrode assembly.

An advantage of the working electrode is that it provides an improved signal to noise ratio by reducing noise and allowing a signal to be produced equivalent to a solid electrode but only using one half or less of the surface area of a solid electrode.

Another advantage of the invention is that the electrode can be used to measure very low concentrations of S an electrochemical signal in an electrolyte (i.e., an ionically conductive material). For example, the electrode can be used in conjunction with a hydrogel system for monitoring glucose levels in a subject (e.g., a human). An electroosmotic electrode (e.g., iontophoresis or reverse iontophoresis electrodes) can be used electrically to draw glucose into the hydrogel. Glucose oxidase (GOD) contained in the hydrogel converts the glucose into gluconic acid and hydrogen peroxide. The electrode subassembly catalyzes the hydrogen peroxide into an electrical signal. This system allows for the continuous and accurate measurement of an inflow of a very small amount of glucose in an electrolyte (e.g., glucose concentrations 10,500, or 1,000 or more times less than the concentration of glucose in blood).

Another advantage is that the electrode assembly and electrode subassembly are easily and economically produced.

A feature of the electrode subassembly of the invention is that it is small and flat, having a total surface area in the range of about 0.1 cm2 to 8.0 cm2. If desired, the electrode subassembly can also be quite thin, such that it has a thickness in the range of about 0.25 μm to 250 μm.

These and other objects, advantages and features of the present invention will become apparent to those persons skilled in the art upon reading the details of the composition, components and size of the invention as set forth below, reference being made to the accompanying drawings forming a part hereof wherein like numbers refer to like components throughout.

FIG. 1 is an overhead schematic view of a conventional electrode one dimensional working electrode.

FIG. 2 is an overhead schematic view of a two dimensional working.

FIG. 3 is an overhead schematic view of a three dimensional working electrode.

FIG. 4 illustrates an example of an operating circuit using working electrode 1, reference electrode 21, and counter electrode 22 with a power source 23 and monitoring device 24. The power source 23 is used to provide voltage to the reference 21 and working 1 electrode to drive the conversion of chemical signal to electrical signal at the catalytic, multidimensional faces of the working 1 electrode. The power source 23 also maintains a fixed potential at the working electrode 1 (where, for example, hydrogen peroxide is converted to molecular oxygen, hydrogen ions, and electrons), which is compared with the potential of the reference electrode 21 during monitoring. The operating circuit also maintains an electrical potential on the working electrode 1 for catalysis of chemical signal that diffuses toward the working electrode 1. The working electrode 1 is electrically connected to a counter electrode 22. The counter electrode 22 consumes electrons generated at the working electrode. The current generated at the working electrode 1 is measured at a position between the working 1 and counter 22 electrode.1 measured relative to the reference electrode 21 as exemplified in FIG. 4 . The electrical current generated at the working electrode 1 is correlated to the amount of glucose in the hydrogel patch, and extrapolated to the concentration of glucose in the subject's bloodstream.

The composition, size and thickness of the electrode assembly can be varied and such variance can affect the time over which the electrode assembly can be used. For example, the hydrogel patches and the electrodes of the present invention used with the electrode assembly are generally designed so as to provide utility over a period of about 24 hours. After that time some deterioration in characteristics, sensitivity, and accuracy of the measurements from the electrode can be expected (e.g., due to accumulation of material on the face of the electrode subassembly), and the electrode subassembly and hydrogel patch should be replaced. The invention contemplates electrode assemblies which are used over a shorter period of time, e.g., 8 to 12 hours or a longer period of time, e.g., 1 to 30 days.

The substantially discontinuous working electrode surfaces of the invention can be used to obtain improved signal to noise ratio and enhanced signal over an finite time when measuring any chemical signal in an finite volume. More specifically, the working electrode of the invention can be used to carry out a method which comprises extracting any biomedically significant substance through the skin of a mammalian subject (e.g., a human patient) and reacting that substance with another substance or substances to form a product which is detectable electrochemically by the production of a signal, which signal is generated proportionally based on the amount of a biologically important or biomedically significant substance drawn into the patch. As indicated in the above-cited patents the ability to withdraw biochemically significant substances such as glucose through skin has been established (see U.S. Pat. Nos. 5,362,307 and 5,279,543). However, the amount of compound withdrawn is often so small that it is not possible to make meaningful use of such methodology in that the withdrawn material cannot be precisely measured and related to any standard. The present invention provides an electrode that is capable of detecting the electrochemical signal at very low levels in a manner that allows for direct, accurate correlation between the amount of signal generated and the amount of the molecule in the human subject.

The invention is remarkable in that it allows for the noninvasive detection and quick, accurate measurement of amounts of a biomedically relevant compound, e.g., glucose, at levels that are 1, 2, or even 3 orders of magnitude less than the concentration of that compound in blood. For example, glucose might be present in blood in-a concentration of about 5 millimolar. However, the concentration of glucose in a hydrogel patch which is used to withdraw glucose through skin as described in the system above is on the order of 2 micromolar to 100 micromolar. Micromolar amounts are 3 orders of magnitude less than millimolar amounts. The ability accurately and quickly to detect glucose in such small concentrations is attained by constructing the electrode assembly and electrode subassembly with the components described herein and the configurations described herein.

Because the amount of signal to be measured may be very small and further because it may be important to measure changes quickly in that signal over short periods of time the multicomponent, multisurface electrode configuration of the invention is valuable in obtaining results. The electrodes of the invention can detect a smaller signal over a shorter period of time as compared to a continuous surface working electrode.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to use the electrode assemblies and subassemblies of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, particular components, etc.), but some deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, surface area is geometric surface area, temperature is in degrees centigrade, and pressure is at or near atmospheric pressure.

The data presented in these examples are computer-simulated (i.e., the data is generated from a computer model of the electrode assembly described herein). The computer model of the invention uses the following parameters:

    • peroxide diffusivity: 1.2×10−5 cm2/sec;
    • glucose diffusivity: 1.3×10−6 cm2/sec;
    • initial peroxide concentration=100 nmol/ml=100 μM; thickness of stagnant layer on top of electrode (the gel layer)=600 microns;
    • electrode thickness=125 micron width for the strip configuration as per FIG. 7 and 125 micron squares for the checkerboard configuration as per FIG. 10;
    • gap (insulator)=125 microns, 250 microns and 500 microns for the strip configuration, as indicated in FIGS. 11, 12, and 13.

Effect of Edges and Radial Diffusion on Peroxide Flux at an Electrode Surface

FIG. 11 provides a computer simulation of the effect of edges and radial diffusion on peroxide flux at an electrode surface. This simulation shows that the peroxide flux on a slotted discontinuous electrode is higher at all positions, and particularly so at and near the edges, as compared to the peroxide flux for a planar electrode.

Peroxide Flux on a Checker Board Electrode

FIG. 12 provides a computer simulation of peroxide flux an a “checker board” electrode; radial and planar diffusion are compared with radial diffusion only. This simulation shows the peroxide flux on a checkerboard relative to the peroxide flux on a planar electrode (with 1D diffusion only). The curves are normalized for the same surface area of the electrode. Also shown is the ratio of the flux for checkerboard divided by the flux for the planar electrode. This ratio curve clearly shows that there is a significant advantage in using a discontinuous surface (such as a checkerboard) as compared to a planar electrode.

Comparison of Checker Board, Slotted, and Solid Electrodes

FIG. 13 is a graph of a computer simulation of results comparing a normalized ratio of mesh to solid electrodes over time. This simulation shows the peroxide flux for slotted and square electrodes (E) with spacing (S) relative (normalized) to the peroxide flux for a 1D planar electrode. In all cases, the results are normalized so that the electrodes have the same surface area. The conclusion from this graph is that the checkerboard (square) electrode is best, followed by the 125 micron/250 micron space slotted electrode, and so on for the remaining electrodes.

Tierney, Michael J., Kurnik, Ronald T., Tamada, Janet

Patent Priority Assignee Title
10039881, Dec 31 2002 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
10041901, Mar 15 2013 Roche Diabetes Care, Inc Electrode configuration for a biosensor
10178954, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
10201301, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
10231654, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
10349874, Sep 29 2009 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
10429250, Aug 31 2009 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
10478108, Apr 19 2007 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
10653317, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
10750952, Dec 31 2002 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
10952611, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
10952652, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
10996184, Mar 15 2013 Roche Diabetes Care, Inc. Electrode configuration for a biosensor
11045147, Aug 31 2009 Abbott Diabetes Care Inc. Analyte signal processing device and methods
11103165, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11150145, Aug 31 2009 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
11272867, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11363975, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11399748, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11471075, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
11538580, Nov 04 2005 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
11612363, Sep 17 2012 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
11635332, Aug 31 2009 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
11696684, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
11793936, May 29 2009 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
11872370, May 29 2009 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
11911151, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
7618522, Oct 31 2003 Cilag GmbH International; Lifescan IP Holdings, LLC Method of reducing interferences in an electrochemical sensor using two different applied potentials
7620438, Mar 31 2006 ABBOTT DIABETES CARE, INC Method and system for powering an electronic device
7653492, Oct 31 2003 Cilag GmbH International; Lifescan IP Holdings, LLC Method of reducing the effect of direct interference current in an electrochemical test strip
7655119, Oct 31 2003 Cilag GmbH International; Lifescan IP Holdings, LLC Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials
7699775, Jun 22 2001 Lifescan IP Holdings, LLC Methods for estimating analyte-related signals, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods
7766829, Nov 04 2005 ABBOTT DIABETES CARE, INC Method and system for providing basal profile modification in analyte monitoring and management systems
7811231, Dec 31 2002 Abbott Diabetes Care Inc Continuous glucose monitoring system and methods of use
7860544, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
7869853, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
7885699, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
7920907, Jun 07 2006 ABBOTT DIABETES CARE, INC Analyte monitoring system and method
7949382, Mar 29 2005 ARKAL, INC Devices, systems, methods and tools for continuous glucose monitoring
7976778, Apr 02 2001 Abbott Diabetes Care Inc Blood glucose tracking apparatus
8066639, Jun 10 2003 Abbott Diabetes Care Inc Glucose measuring device for use in personal area network
8103456, Jan 29 2009 ABBOTT DIABETES CARE, INC Method and device for early signal attenuation detection using blood glucose measurements
8112240, Apr 29 2005 Abbott Diabetes Care Inc Method and apparatus for providing leak detection in data monitoring and management systems
8123686, Mar 01 2007 ABBOTT DIABETES CARE, INC Method and apparatus for providing rolling data in communication systems
8149117, May 08 2007 Abbott Diabetes Care Inc Analyte monitoring system and methods
8162829, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8162830, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8175673, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8177716, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8187183, Dec 31 2002 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
8224413, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8226555, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8226557, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8226558, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8226891, Mar 31 2006 ABBOTT DIABETES CARE, INC Analyte monitoring devices and methods therefor
8231532, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8235896, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8236242, Apr 02 2001 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
8255031, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8260392, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8265726, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8268243, Apr 02 2001 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
8273022, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8275439, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8287454, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8306598, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8346336, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8346337, Nov 05 2007 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8353829, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8357091, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8362904, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
8366614, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8372005, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8380273, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8391945, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8409131, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8437966, Apr 04 2003 Abbott Diabetes Care Inc Method and system for transferring analyte test data
8456301, May 08 2007 ABBOTT DIABETES CARE, INC Analyte monitoring system and methods
8461985, May 08 2007 ABBOTT DIABETES CARE, INC Analyte monitoring system and methods
8465425, Nov 01 2005 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8473021, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8473220, Jan 29 2009 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
8480580, Apr 30 1998 ABBOTT DIABETES CARE, INC Analyte monitoring device and methods of use
8483974, Apr 04 2003 Abbott Diabetes Care Inc Method and system for transferring analyte test data
8512239, Jun 10 2003 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
8560250, Apr 04 2003 Abbott Diabetes Care Inc Method and system for transferring analyte test data
8585591, Nov 04 2005 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
8593287, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
8597189, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8597575, Mar 31 2006 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
8612159, Apr 30 1998 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8617071, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8622903, Dec 31 2002 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
8622906, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8641619, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8647269, Jun 10 2003 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
8649841, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8660627, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8665091, May 08 2007 Abbott Diabetes Care Inc.; Abbott Diabetes Care Inc Method and device for determining elapsed sensor life
8666469, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8668645, Jan 02 2001 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8670815, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8672844, Apr 30 1998 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8676513, Jan 29 2009 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
8682598, Apr 04 2003 Abbott Diabetes Care Inc Method and system for transferring analyte test data
8688188, Nov 01 2005 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8732188, Feb 18 2007 ABBOTT DIABETES CARE, INC Method and system for providing contextual based medication dosage determination
8734346, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8734348, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8738109, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8744545, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8765059, Apr 02 2001 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
8771183, Dec 31 2002 Abbott Diabetes Care Inc Method and system for providing data communication in continuous glucose monitoring and management system
8774887, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8840553, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8880137, Apr 30 1998 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
8915850, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8920319, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
8930203, Feb 18 2007 Abbott Diabetes Care Inc Multi-function analyte test device and methods therefor
8974386, Apr 30 1998 ABBOTT DIABETES CARE, INC Analyte monitoring device and methods of use
8993331, Aug 31 2009 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
9000929, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9011331, Apr 30 1998 Abbott Diabetes Care Inc Analyte monitoring device and methods of use
9011332, Jan 02 2001 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9014773, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9020573, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9035767, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9039975, Mar 31 2006 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
9042953, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9066694, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9066695, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9066697, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9066709, Jan 29 2009 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
9072477, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9078607, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9095290, Mar 01 2007 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
9177456, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9226701, Apr 28 2009 Abbott Diabetes Care Inc Error detection in critical repeating data in a wireless sensor system
9314195, Aug 31 2009 Abbott Diabetes Care Inc Analyte signal processing device and methods
9314198, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9320461, Sep 29 2009 Abbott Diabetes Care Inc Method and apparatus for providing notification function in analyte monitoring systems
9323898, Nov 04 2005 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
9326714, Apr 30 1998 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9326716, Nov 01 2005 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9477811, Apr 02 2001 Abbott Diabetes Care Inc Blood glucose tracking apparatus and methods
9498159, Jan 02 2001 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9574914, May 08 2007 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
9610034, Jan 02 2001 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
9625413, Mar 31 2006 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
9649057, May 08 2007 Abbott Diabetes Care Inc. Analyte monitoring system and methods
9669162, Nov 04 2005 ABBOTT DIABETES CARE, INC Method and system for providing basal profile modification in analyte monitoring and management systems
9730584, Jun 10 2003 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
9750439, Sep 29 2009 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
9801545, Mar 01 2007 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
9949678, May 08 2007 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
9962091, Dec 31 2002 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
9968302, Aug 31 2009 Abbott Diabetes Care Inc. Analyte signal processing device and methods
9968306, Sep 17 2012 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
9980669, Nov 07 2011 Abbott Diabetes Care Inc Analyte monitoring device and methods
Patent Priority Assignee Title
3954925, Dec 20 1972 GKSS- FORSCHUNGSZENTRUM GEESTHACHT GMBH, Method of making semi-permeable asymmetric membranes for reverse osmosis
4073713, Sep 24 1975 The Yellow Springs Instrument Company, Inc. Membrane for enzyme electrodes
4241150, Jul 30 1979 Energy Development Associates, Inc. Method for control of edge effects of oxidant electrode
4288507, Jul 30 1979 Energy Development Associates, Inc. Control of edge effects of oxidant electrode
4324257, Feb 20 1978 HONEYWELL B V AMSTERDAM,A SUBSIDIARY OF THE NETHERLANDS OF HONEYWELL INC A DE CORP Device for the transcutaneous measurement of the partial oxygen pressure in blood
4388166, Aug 14 1979 Tokyo Shibaura Denki Kabushiki Kaisha Electrochemical measuring apparatus provided with an enzyme electrode
4416274, Feb 23 1981 JMW, ACQUISITION CO A CORP OF UT Ion mobility limiting iontophoretic bioelectrode
4457748, Jan 11 1982 ALZA CORPORATION, A CORPORATION OF DE Non-invasive diagnosis method
4477971, Nov 06 1981 JMW, ACQUISITION CO A CORP OF UT Iontophoretic electrode structure
4546312, Mar 04 1982 L OREAL, A FRENCH CORP Cell for the measurement of the dielectric constant of viscous or pasty substances
4571292, Aug 12 1982 Case Western Reserve University Apparatus for electrochemical measurements
4633879, Nov 16 1979 Lec Tec Corporation Electrode with disposable interface member
4655880, Aug 01 1983 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
4702732, Dec 24 1984 TRUSTEES OF BOSTON UNIVERSITY, A CORP OF MA Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
4722726, Feb 12 1986 ALZA CORPORATION, A CORPORATION OF DE Method and apparatus for iontophoretic drug delivery
4722761, Mar 28 1986 NDM, INC Method of making a medical electrode
4731049, Jan 30 1987 Ionics, Incorporated Cell for electrically controlled transdermal drug delivery
4752285, Mar 19 1986 UNIVERSITY OF UTAH RESEARCH FOUNDATION, THE, SALT LAKE CITY, UT A CORP OF UT Methods and apparatus for iontophoresis application of medicaments
4781798, Apr 19 1985 The Regents of the University of California Transparent multi-oxygen sensor array and method of using same
4871440, Jul 06 1987 SANKYO COMPANY LTD Biosensor
4968297, May 09 1989 Iomec, Inc. Iontophoretic electrode with solution containment system
5036861, Jan 11 1990 Method and apparatus for non-invasively monitoring plasma glucose levels
5135480, Jul 10 1986 Elan Transdermal Limited Transdermal drug delivery device
5140985, Aug 01 1991 Noninvasive blood glucose measuring device
5250022, Sep 25 1990 Rutgers, The State University of New Jersey Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose
5279543, Jan 29 1988 The Regents of the University of California Device for iontophoretic non-invasive sampling or delivery of substances
5362307, Jan 24 1989 Regents of the University of California, The Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
5423739, Mar 30 1990 ALZA Corporation Device and method for iontophoretic drug delivery
5443442, Mar 30 1990 ALZA Corporation Method and apparatus for controlled environment electrotransport
5730714, Jan 29 1988 Regents of the University of California, The Method for the iontophoretic non-invasive determination of the in vivo concentration level of glucose
5735273, Sep 12 1995 Animas Technologies LLC Chemical signal-impermeable mask
5771890, Jun 24 1994 Animas Technologies LLC Device and method for sampling of substances using alternating polarity
5827183, Sep 12 1995 Animas Technologies LLC Method of measuring chemical concentration iontophoretically using impermeable mask
6139718, Mar 25 1997 Lifescan IP Holdings, LLC Electrode with improved signal to noise ratio
DE3737059,
EP453283,
EP304304,
JP362133937,
SU1827524,
WO9012314,
WO9324828,
WO9502357,
WO9600109,
WO9600110,
WO9702811,
WO9724059,
WO9748979,
////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Dec 02 2002Cygnus, Inc.(assignment on the face of the patent)
Mar 23 2005CYGNUS, INC Animas Technologies LLCASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0164180075 pdf
Dec 04 2017Animas CorporationANIMAS LLCCHANGE OF NAME SEE DOCUMENT FOR DETAILS 0493640900 pdf
Apr 03 2019ANIMAS, LLCLifescan IP Holdings, LLCASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0495360792 pdf
Date Maintenance Fee Events
Mar 22 2005LTOS: Pat Holder Claims Small Entity Status.
May 17 2005M2551: Payment of Maintenance Fee, 4th Yr, Small Entity.
May 17 2005M2554: Surcharge for late Payment, Small Entity.
Oct 31 2005ASPN: Payor Number Assigned.
Jan 09 2007STOL: Pat Hldr no Longer Claims Small Ent Stat
Feb 04 2009M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Feb 06 2013M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jan 04 20084 years fee payment window open
Jul 04 20086 months grace period start (w surcharge)
Jan 04 2009patent expiry (for year 4)
Jan 04 20112 years to revive unintentionally abandoned end. (for year 4)
Jan 04 20128 years fee payment window open
Jul 04 20126 months grace period start (w surcharge)
Jan 04 2013patent expiry (for year 8)
Jan 04 20152 years to revive unintentionally abandoned end. (for year 8)
Jan 04 201612 years fee payment window open
Jul 04 20166 months grace period start (w surcharge)
Jan 04 2017patent expiry (for year 12)
Jan 04 20192 years to revive unintentionally abandoned end. (for year 12)